

Maternal Urinary Phthalate Metabolites are Associated with Lipidomic Signatures Among Pregnant Women in Puerto Rico

Pahriya Ashrap¹, Max T. Aung², Deborah J. Watkins¹, Bhramar Mukherjee³, Zaira Rosario-Pabón⁴, Carmen M. Vélez-Vega⁴, Akram Alshawabkeh⁵, José F. Cordero⁶, John D. Meeker^{1*}

¹University of Michigan School of Public Health, Department of Environmental Health Sciences, Ann Arbor, Michigan, United States

²University of California, San Francisco, Department of Obstetrics, Gynecology, and Reproductive Sciences, Program on Reproductive Health and the Environment, San Francisco, California, United States

³University of Michigan School of Public Health, Department of Biostatistics, Ann Arbor, Michigan, United States

⁴University of Puerto Rico Graduate School of Public Health, UPR Medical Sciences Campus, San Juan, Puerto Rico

⁵ College of Engineering, Northeastern University, Boston, Massachusetts, United States

⁶ Department of Epidemiology and Biostatistics, University of Georgia, Athens, Georgia, United States

*Corresponding author: John D. Meeker, University of Michigan School of Public Health, Department of Environmental Health Sciences, 1415 Washington Heights, Ann Arbor, Michigan 48109, USA, email: meekerj@umich.edu, telephone: 1.734.764.7184

1 **ABSTRACT**

2
3 **Background:** Phthalates have been reported to alter circulating lipid concentrations in animals,
4 and investigation of these associations in humans will provide greater understanding of potential
5 mechanisms for health outcomes.

6
7 **Objective:** to explore associations between phthalate metabolite biomarkers and lipidomic profiles
8 among pregnant women (n = 99) in the Puerto Rico PROTECT cohort.

9
10 **Methods:** We measured 19 urinary phthalate metabolites during 24-28 weeks of pregnancy.
11 Lipidomic profiles were identified from plasma samples by liquid chromatography-mass
12 spectrometry-based shotgun lipidomics. Relationships between phthalates and lipid profiles were
13 estimated using compound-by-compound comparisons in multiple linear regression and dimension
14 reduction techniques. We derived sums for each lipid class and sub-class (saturated,
15 monounsaturated, polyunsaturated) which were then regressed on phthalates. Associations were
16 adjusted for false discovery.

17
18 **Results:** After controlling for multiple comparisons, 33 phthalate-lipid associations were
19 identified (q-value<0.05), and diacylglycerol 40:7 and plasmenyl-phosphatidylcholine 35:1 were
20 the most strongly associated with multiple phthalate metabolites. Metabolites of di-2-ethylhexyl
21 phthalate, bis(2-ethylhexyl) phthalate, dibutyl phthalates, and diisobutyl phthalate were associated
22 with increased ceramides, lysophosphatidylcholines, lysophosphatidylethanolamines, and
23 triacylglycerols, particularly those containing saturated and monounsaturated fatty acid chains.

24
25 **Significance:** Characterization of associations between lipidomic markers and phthalates during
26 pregnancy will yield mechanistic insight for maternal and child health outcomes.

27
28 **Keywords:** Biomarkers; Exposure; Phthalates; Lipidomics; Puerto Rico

29
30
31 **Impact Statement:** This study leverages emerging technology to evaluate lipidome-wide
32 signatures of phthalate exposure during pregnancy. Circulating lipids are critical for biological
33 processes including inflammation, cell-to-cell communication, and metabolism. Therefore, lipid
34 signatures of phthalate exposure provide insight into potential toxicological mechanisms.
35 Characterization of these mechanisms are relevant for informing the etiology of maternal and
36 children's health outcomes.

37
38
39
40
41
42
43
44
45
46

47 **INTRODUCTION**

48
49 Phthalates are a group of chemicals that are found in numerous commercially available
50 products like food packaging, vinyl flooring, pharmaceuticals, and personal care products [1, 2].
51 According to biomonitoring reports, human exposure to phthalates is ubiquitous for children and
52 adults [3, 4], including pregnant women and their fetuses due to transplacental passage of
53 phthalates [5]. Prenatal and early-life exposure to phthalates has been related to adverse pregnancy
54 events [6-11] and childhood developmental and cardiometabolic outcomes [12-16].

55 One of the proposed mechanisms of action and pathways involved in early life phthalate-
56 induced adverse effects is disruption of lipids. Animal studies suggest that phthalates influence
57 circulating lipid levels and lipid signaling [17-20], by interfering with peroxisome-proliferator
58 active receptor gamma (PPAR γ) [21, 22]. This points to the possibility that a similar mechanism
59 is at play for humans. However, the relationship between prenatal phthalate exposure and lipid
60 metabolism has rarely been investigated among humans. In the limited existing research on
61 humans, the focus has been on the relationship between maternal phthalates and specific lipids
62 such as cholesterol and triglycerides [23-25]. Application of lipidomic profiling (lipidomics) of
63 global cellular lipids in a complex biological sample [26], a branch of metabolomics, may inform
64 research on the discovery of new potential biomarkers of effect or patterns of change related to
65 environmental exposures, including phthalates. Only one study to date has examined the
66 association between maternal metabolomics, including lipid metabolites, and environmental
67 phthalates in pregnant women (n = 115) from the Center for the Health Assessment of Mothers
68 and Children of Salinas (CHAMACOS) cohort [27]. The authors found significant relationships
69 between maternal phthalate exposure and plasma free fatty acids, lysolipids, ceramides, and
70 triacylglycerols.

71 Our previous research in the Puerto Rico PROTECT birth cohort found associations
72 between prenatal phthalate urine metabolite levels and increased odds of preterm birth [28, 29]. In
73 the PROTECT cohort, we also assessed the relationship between maternal lipidomic profiles and
74 adverse birth outcomes and observed numerous significant lipid signatures for spontaneous
75 preterm birth [30]. In the current study, we sought to explore the association between maternal
76 phthalate metabolite biomarkers and lipidomic profiles among pregnant women (n = 99) in the
77 PROTECT birth cohort. In doing so, we contribute to the characterization of the potential
78 mechanism of action for phthalate exposure. We also highlight the utility of lipidomics as a tool
79 in environmental epidemiology in detecting intermediate endogenous biomarkers of phthalate
80 exposures.

81 **METHODS**

82

83 *Study sample*

84 This study sample is an exploratory subset of the Puerto Rico PROTECT cohort. The
85 PROTECT cohort began recruitment in 2010 through funding from the National Institute of
86 Environmental Health Sciences Superfund Research Program. Study participants were recruited
87 in the first or second trimester of pregnancy (median 14 weeks gestation). The research protocol
88 was approved by the Ethics and Research Committees of the University of Puerto Rico and
89 participating clinics, the University of Michigan, Northeastern University, and the University of
90 Georgia. Inclusion criteria for recruitment included: participant age between 18 and 40 years;
91 residence in the Northern Karst aquifer region; disuse of oral contraceptives three months before
92 pregnancy; disuse of in vitro fertilization; and no indication of medical records for major
93 obstetrical complications, including pre-existing diabetes. Prenatal spot urine and blood samples
94 were collected during the third study visit at approximately 26 weeks of gestation. From the

95 larger cohort of 2070 pregnant women, we randomly sampled 100 women with the goal of
96 achieving a 1:2 case-control ratio of preterm birth, which included 31 cases and 69 controls. We
97 created and applied inverse probability weights to account for the sampling approach [31].

98 *Urinary phthalate measurements*

99 Urine was collected in polypropylene containers, divided into aliquots, and frozen at -80
100 °C until shipment overnight to the Division of Laboratory Sciences at the Centers for Disease
101 Control and Prevention (CDC) for analysis. Urinary concentrations of 15 phthalates, two
102 DEHTP, and two DINCH metabolites were measured using on-line solid phase extraction
103 coupled with isotope dilution-high performance liquid chromatography-electrospray ionization-
104 tandem mass spectrometry as previously described [32-34]. Measured phthalate metabolites
105 comprised mono(2-ethylhexyl) phthalate (MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate
106 (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono(2-ethyl-5-carboxypentyl)
107 phthalate (MECPP), mono-benzyl phthalate (MBzP), monocarboxyooctyl phthalate (MCOP),
108 mono-isononyl phthalate (MNP), mono-oxoisononyl phthalate (MONP), monocarboxynonyl
109 phthalate (MCNP), mono (3-carboxypropyl) phthalate (MCP), mono-ethyl phthalate (MEP),
110 mono-n-butyl phthalate (MBP), mono-3-hydroxybutyl phthalate (MHBP), mono-isobutyl
111 phthalate (MiBP) and mono-2-hydroxy-iso-butyl phthalate (MHiBP). Measured DEHTP
112 metabolites comprised mono-2-ethyl-5-carboxypentyl terephthalate (MECPTP) and mono-2-
113 ethyl-5-hydroxyhexyl terephthalate (MEHHTP) [35, 36]. Measured DINCH metabolites were
114 cyclohexane-1,2-dicarboxylic acid monohydroxy isononyl ester (MHiNCH) and cyclohexane-
115 1,2-dicarboxylic acid monocarboxy isooctyl ester (MCOCH) [33]. The sum of di-2-ethylhexyl
116 phthalate metabolites (Σ DEHP) was calculated by adding the molar fractions of MEHP,
117 MEHHP, MEOHP, and MECPP. To achieve unit comparability, Σ DEHP (nmol/ml) was

118 multiplied by the molecular weight (MW) of MEHP (278.348 g/mol). The resulting units were
119 ng/ml. Specific gravity (SG) was measured using a handheld digital refractometer (Atago Co.,
120 Ltd., Tokyo, Japan) at the University of Puerto Rico Medical Sciences Campus at the time of
121 sample collection. Values below the limit of detection (LOD) were imputed with the metabolite-
122 specific $LOD/\sqrt{2}$ [37].

123 *Lipidome measurement*

124 Plasma lipids were extracted from blood plasma samples provided by women at the third
125 study visit using a modified Bligh-Dyer method [38] using liquid-liquid extraction at room
126 temperature after spiking with internal standards. Analysis of lipids was performed on reversed
127 phase high-performance liquid chromatography (HPLC), followed by mass spectrometry (MS)
128 analysis that alternates between MS and data dependent MS2 scans using dynamic exclusion in
129 both positive and negative polarity and yields excellent separation of all classes of lipids. The
130 lipids are quantified using Multiquant and normalized by internal standards. Measurements are
131 semi-quantitative and are based on the relative abundance of peak intensities. Quality controls
132 (QC) are prepared by pooling equal volumes of each sample, in addition to a well characterized
133 plasma pools, and are injected at the beginning and end of each analysis and after every 10
134 sample injections, to provide a measurement of the system's stability and performance as well as
135 reproducibility of the sample preparation method [39].

136 Lipids were identified using the LipidBlast [40] library (computer-generated tandem
137 mass spectral library of 212,516 spectra covering 119,200 compounds from 26 lipid compound
138 classes), by matching the product ions MS/MS data. The method allowed us to measure 587
139 lipids belonging to 19 different lipid classes which include acylcarnitine (AcyICN), ceramides

140 (CER), cholesterol esters (CE), diacylglycerols (DG), glucosylceramides(GlcCer), free fatty
141 acids (FFA), fatty acid esters of hydroxy fatty acids (FAHFA), lysophosphatidylcholine
142 (LysoPC), lysophosphatidylethanolamine (LysoPE), phosphatidic acid (PA),
143 phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG),
144 plasmeyl-phosphatidylcholine (PLPC), plasmeyl-phosphatidylethanolamine (PLPE),
145 phosphatidylinositol (PI), phosphatidylserine (PS), sphingomyelin (SM), and triacylglycerol
146 (TG). All individual lipids will be mentioned with the nomenclature as X:Y, where X is the
147 length of the carbon chain and Y, the number of double bonds.

148 *Statistical Analysis*

149
150 Inverse probability weighting of over-representation of preterm birth cases was applied to
151 all statistical analyses presented in this analysis in order for our study to resemble the proportions
152 of preterm birth in a general population [31]. 11 phthalate metabolites (MEHP, MEHHP, MEOHP,
153 MECPP, MBzP, MCOP, MCNP, MCPP, MEP, MBP, MiBP) and the sum of DEHP metabolites
154 (Σ DEHP) were included in the statistical analysis. Four phthalate metabolites (MNP, MONP,
155 MHBP, and MHiBP), two DEHTP metabolites (MECPTP, MEHHTP), two DINCH metabolites
156 (MHiNCH, MCOCH) had >15% data missing, therefore were excluded from the analysis.

157 The group sum of the individual lipids' relative abundance that belong to each lipid class
158 (n=19) were calculated to evaluate lipid classes. Considering lipid classes containing saturated,
159 mono-unsaturated, and polyunsaturated fatty acids (PUFAs) may present different biological
160 patterns, 45 lipid subgroups (saturated, mono-unsaturated, poly-unsaturated) were created by
161 grouping lipids based on a priori knowledge of lipid class and the number of double bonds in each
162 lipid species. Sum of lipids' relative abundance were also created for the 45 sub-groups.
163 Descriptive statistics for lipids were computed to examine their distributions. Spearman correlation

164 coefficients were calculated between lipid class, lipid sub-groups and phthalates to visualize crude
165 associations.

166 Multiple statistical strategies were used to assess relationships between lipid profiles and
167 phthalates. The relative abundance of individual lipids, group sums, and sub-groups sums were
168 log-transformed due to their skewed distribution. Subsequently, the log-transformed individual
169 lipids, group sums, and sub-group sums were normalized among individuals (rows) by standard
170 normal variate (SNV) normalization. Covariates were selected based on *a priori* considerations
171 from literature review of factors that would influence both lipid concentrations and phthalate
172 levels. Multiple linear regression models were fitted to evaluate the association between phthalates
173 and the lipidome, adjusting for maternal age, maternal education, fetal sex, pre-pregnancy BMI,
174 and weight gain during pregnancy. 1) Single pollutant models were performed for each log-
175 transformed and standardized relative abundance of lipid (n=587) regressing on phthalate
176 metabolites (n=12). False discovery rate (FDR) adjusted p-values (q-values), a commonly used
177 method of adjusting for multiple comparisons in lipidomics studies, were used to account for
178 multiple comparisons. 2) Sums for each lipid class (p=19) and lipid sub-group (p=45) (saturated,
179 monounsaturated, polyunsaturated were then regressed on each phthalate metabolite (n=12). The
180 results are presented as estimated percentage changes of lipids, lipid group sums, or sub-group
181 sums with the corresponding 95% confidence intervals and p values per interquartile range (IQR)
182 change in phthalate metabolite concentration.

183 184 **RESULTS**

185 186 *Descriptive statistics*

187 Demographic and health characteristics of the women in our study are reported in
188 Supplementary Table 1. The mean age of study participants at the time of enrollment was 26.5

189 years (standard deviation = 5.7). A majority of participants (77%) had some level of higher
190 education experience. In this sample, 44% of participants reported that they were unemployed, and
191 75% of participant household incomes were below \$50k. Approximately 37% of participants had
192 pre-pregnancy body mass index of greater than 25 kg/m². Most participants did not report smoking
193 (98%) or drinking (92%) during pregnancy.

194 *Phthalates and Lipidome-wide metabolite associations*

195 **Figure 1** is a Manhattan plot indicating $-\log_{10}(\text{p-value})$ for phthalates in association with
196 individual lipids. The dashed line indicates p value = 0.001. The 33 most significant associations
197 after adjusting for false discovery rate (p value < 0.001, q value < 0.05) were annotated with the
198 individual lipid in the figure. The Manhattan plot depicts that the lipid metabolites from the DG
199 family were mainly associated with DEHP metabolites, while all of the significant signaling lipids
200 from the CER class were found to be associated with MCNP, MCPP, MBP, and MiBP. Among
201 these top associations, the most prevalent and significant signals were for lipid metabolite DG 40:7
202 in association with all four DEHP metabolites (MEHP, MEHHP, MEOHP, and MECPP), MCPP,
203 and MBP. This was also confirmed on a feature level with a Euler diagram (**Supplementary**
204 **Figure 1**) showing the overlap between significant lipid metabolite signals found across different
205 phthalate parent compounds. Among all the lipids with significant signals, DG 40:7 overlapped
206 within most of the ellipses. Another such signal is PLPC 35:1, where MEHHP, MEOHP, MECPP,
207 MBP, and MiBP were significantly associated with this lipid metabolite from the PLPC family. In
208 addition, urinary MECPP and MCPP concentrations were significantly associated with lipid
209 metabolite LysoPE 18:0 from the LysoPE class. MBzP, MCOP, and MEP were not associated with
210 any lipid metabolite in these individual models (**Figure 1 & Supplementary Table 2**).

211 *Saturation subgroup associations with pregnancy phenotypes*

212 A list of the individual lipids within each saturation group is reported in **Supplementary**
213 **Table 3**. Associations between phthalates and the summation of individual lipid metabolites based
214 on the degree of saturation in fatty acid hydrocarbon tails are presented in **Figure 2**. Significant
215 associations after false discovery rate correction (p value <0.001 & q value <0.05) were annotated
216 for lipid subclass with color indicating association direction, with red representing a positive
217 association and blue indicating a negative association. The effect estimates and 95% confidence
218 intervals of the significant associations are also presented in **Supplementary Table 4**. Nearly all
219 significant associations between phthalates and lipid subgroups were positive. The three oxidative
220 DEHP metabolites, MEHHP, MEOHP, MECPP, as well as the summary measurement Σ DEHP
221 were all positively associated with increased saturated CER, saturated and mono-unsaturated
222 LysoPE and PA, and saturated TG. Higher MECPP was additionally associated with mono-
223 unsaturated CER as well as saturated and mono-unsaturated LysoPC.

224 For increased MCPP concentrations, we observed higher saturated and poly-unsaturated
225 CER, saturated and mono-unsaturated LysoPE, and mono-unsaturated PE levels. The only
226 negative association was found between increased MCPP concentrations and lower saturated FFA.
227 The DBP metabolite MBP was associated with higher levels of saturated CER, PE, and TG, as
228 well as mono-unsaturated CER, PA, and PE. The DiBP metabolite MiBP was associated with
229 higher mono-unsaturated FFA and PA, in addition to saturated CER, PC, and TG. MBzP, MCOP,
230 MCNP, and MEP were not significantly associated with any subgroup lipid class.

231 ***Whole lipid classes associations with pregnancy phenotypes***

232 The heat map in **Figure 3** shows the relationships between phthalate metabolites and lipid
233 classes. Spearman ρ ranged from -0.22 to 0.27. Correlations between MECPP with LysoPC
234 ($\rho=0.27$) and LysoPE ($\rho=0.25$) were among the most significant and positive, while the correlation

235 between MEHP and FFA ($\rho=-0.22$) was the most negative. **Figure 4** shows forest plots of the
236 associations between phthalates and whole lipid classes. Among the lipid classes including CER,
237 LysoPC, LysoPE, and TG, we observed the following positive associations (p value <0.001 & q
238 value <0.05) with Σ DEHP (LysoPE), MECPP (CER, LysoPC, LysoPE), MCPP (CER, LysoPE),
239 and MiBP (TG) when clustering all lipid metabolites into their highest level of organization.
240 **Supplementary Table 5** lists the effect estimates and 95% confidence intervals of these
241 associations.

242 DISCUSSION

243
244 Using a comprehensive lipidomics platform including almost six hundred lipid species, we
245 explored the associations between phthalates and three hierarchical levels of lipid organization: (1)
246 individual lipidome-wide metabolites, (2) subgroup clustering based on hydrocarbon chain
247 saturation, and (3) whole lipid classes. We found evidence of associations between phthalates and
248 each level of these organizational hierarchies of lipids. At the lipidome-wide level of individual
249 metabolites, biomarkers of exposure to DEHP, MCPP, and MBP were associated with lipid
250 metabolites from the DG family (DG 40:7) and lipids from the CER class. For lipid saturation
251 subgroups, significant positive associations were observed for DEHP exposure biomarkers and
252 saturated CER, mono-unsaturated CER, saturated LysoPC, mono-unsaturated LysoPC, and
253 saturated TG, whereas MECPP was inversely associated with saturated FFA. When we evaluated
254 the broadest level of whole lipid classes, a variety of phthalates are positively associated with CER,
255 LysoPC, LysoPE, and TG lipid classes. The direction of associations indicated that higher
256 concentrations of phthalates were largely associated with increased levels of all of the most
257 strongly associated lipid classes. There was not substantive evidence of associations for phthalates
258 in relation to whole lipid classes such as PA and PE, even though the analysis on the saturation

259 subgroup level revealed associations with PA and PE lipids containing saturated and mono-
260 unsaturated fatty acids.

261 We observed some variation in signatures from lipidome-wide analysis to lipid class
262 analysis, and among distinct DG and PLPC classes. This supports the need to measure the
263 associations between phthalates and lipids at an omics-scale to identify important specific lipid-
264 derived biomarkers of maternal phthalate exposure on lipid disruption that would not be identified
265 with less precise analyses of whole aggregate lipid classes. We generated a list of 20 individual
266 lipids across several classes (DG, CER, LysoPE, PLPC, and FFA) that had robust significant
267 associations after false discovery rate correction and may be used to uniquely characterize the
268 lipidomic responses induced by exposure to different phthalate parent compounds
269 (**Supplementary Table 1**). Among these lipids, DG 40:7 and PLPC 35:1 were the most
270 significantly associated with exposure to multiple phthalates and may have high predictability for
271 phthalate-induced disruption during pregnancy.

272 While there is some variation in signatures from lipidome-wide analysis to lipid class
273 analysis, changes to the individual lipidome (represented by PLPC, LysoPE, CER lipids) related
274 to phthalates (DEHP, DBP, and DiBP metabolites) were also observed in the changes of lipid-
275 class and sub-class level analysis. For lipid classes including CER, LysoPC, LysoPE, and TG, we
276 observed positive associations with Σ DEHP (LysoPE), MECPP (CER, LysoPC, LysoPE), MCPP
277 (CER, LysoPE), and MiBP. These increases in lipid classes associated with DEHP metabolite
278 concentrations are consistent with previous reports from animal studies showing that exposure to
279 phthalates, particularly DEHP, influence circulating lipid levels and lipid signaling [17-20, 41]. In
280 contrast, a recent study reported that embryonic exposure to DEHP and DBP in zebrafish
281 significantly reduced the levels of individual lipids from the TG and DG classes [42].

282 Complementary enrichment analysis using proteomic data revealed biological processes
283 associated with DBP (xenobiotic stimulus, lipoprotein metabolism, lipid catabolism, and
284 regulation of FA and TG catabolism) and DEHP (lipase activity regulation, lipid absorption, lipid
285 catabolism and metabolism) [42]. As noted in the introduction, one suggested mechanism is that
286 phthalates, known as PPAR-agonists, are interfering with peroxisome-proliferator active receptor
287 gamma (PPAR γ) and therefore disrupting lipid metabolism [21, 22]. PPAR γ is a member of the
288 nuclear receptor superfamily that plays critical physiological roles regulating lipid metabolism [43,
289 44]. It is possible that PPAR γ may serve as a mediator for maternal phthalate exposure and
290 disruption of lipids. Previous studies have reported that PPAR γ activation can increase both
291 esterification as well as lipolysis [45, 46], which provided evidence for the increased levels of
292 single chain lipid signals in our analysis, including the FFA, DG, and LysoPC, LysoPE families.

293 For lipid saturation subgroups, significant phthalate-induced lipid increases were
294 exclusively observed for several lipid subgroups with saturated and mono-saturated carbon chains
295 and DEHP metabolites (MEHHP, MEOHP, MECPP), MCPP, DBP metabolite (MBP), and DiBP
296 metabolite (MiBP). The significance of the association was particularly related to the saturation of
297 the lipid classes. All of the lipid groups in the above-mentioned associations contain saturated or
298 mono-unsaturated hydrocarbon chains except for the associations between MCPP and poly-
299 unsaturated CER. Evidence from limited human studies have shown that increased levels of
300 saturated and/or mono-unsaturated lipids can have negative effects on pregnancy and poor birth
301 outcomes [47-49]. Therefore, the positive signals we observed between phthalates and saturated
302 and mono-unsaturated lipid classes may be a proxy mechanism or mediator for suspected adverse
303 effects of phthalates on pregnancy outcomes. On the other hand, the beneficial effects of the poly-
304 unsaturated fatty acids were widely studied in previous literature [49, 50]. Formal mediation

305 studies will contribute towards better understanding the potential for poly-unsaturated fatty acids
306 to diminish the toxic effects of phthalates.

307 Previous research on this population has found that MBP and MiBP, biomarkers for DBP
308 and DiBP exposure, were associated with increased odds of preterm birth, and urinary metabolites
309 measured later in the pregnancy were more strongly associated with preterm birth [7]. Two other
310 studies in Boston [8] and Mexico City [51] have also reported an association between DBP and
311 DiBP metabolites and spontaneous preterm birth in pregnant women. Changes in the lipid classes
312 such as FFA, CE, DG, and PLPE, have been related to alteration of gestational length in recently
313 published work on the same Puerto Rico cohort [30]. Further, levels of multiple individual lipids
314 and lipid classes (FFA, CER, PA, PE, and TG) were associated with phthalate metabolites MBP
315 and MiBP in the present work. While our findings need to be confirmed, these findings support
316 the hypothesis that disruption of lipid levels may be a possible pathway mediating phthalates and
317 adverse pregnancy outcomes.

318 Our study employed a lipidome-wide analysis in relation to maternal phthalate
319 exposure, while previous studies of the relationship between phthalate concentrations and lipids
320 have been limited to animal studies or studies on targeted lipids such as triglyceride, LDL, and
321 HDL. The extensive repertoire of lipid metabolites that were measured within the maternal
322 lipidome is an important extension of previous research, as this provides an unprecedented
323 opportunity to consider the maternal plasma lipidome in the context of maternal-neonate health.
324 Importantly, this study contributes to the evolving evidence on the disrupting role of phthalates,
325 most notably with DEHP metabolites on lipids, and is among the first to present these associations
326 on a lipidomic scale.

327 There are a few limitations of this study. The analysis was limited by a fairly small sample
328 size. While the results of this exploratory analysis are biologically plausible and supported by
329 evidence derived from animal studies showing similar results, confirmation in larger diverse
330 cohorts will be required in the future. Because of the cross-sectional nature of the study, windows
331 of vulnerability during pregnancy were not evaluated. Given that phthalate exposure and lipid
332 profiles change across the duration of pregnancy, it is important for future longitudinal studies to
333 evaluate the temporality of the associations between phthalates and maternal lipidome throughout
334 gestation. Although our analyses were adjusted for important potential confounders, residual
335 confounding due to unmeasured variables (e.g., dietary factors) may still exist that could
336 alternatively explain, at least in part, the observed associations.

337 **Conclusions**

338 We employed a semi-targeted lipidomics analysis with more than five hundred measured
339 metabolites in maternal plasma samples, which provided an opportunity to examine the
340 relationship between urine phthalate metabolite concentrations with the plasma lipidome. We
341 reported associations of maternal exposure to DEHP, DOP, DBP, and DiBP on omics scale plasma
342 lipids and lipid classes among pregnant women, particularly with those containing saturated and
343 monounsaturated fatty acid chains. We identified new potential lipidomic markers of phthalate-
344 induced disruption during pregnancy. These results provide new insights into the relationship
345 between maternal phthalate exposure and lipidomic profiles during gestation.

346
347

Data availability

Data utilized for this analysis can be obtained by reasonable request by contacting the corresponding author (JDM, meekerj@umich.edu)

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the NIEHS, EPA, or Centers for Disease Control and Prevention (CDC). Use of trade names is for identification only and does not imply endorsement by the CDC, the Public Health Service, or the US Department of Health and Human Services.

Author Contributions

P.A.: Statistical analysis; Investigation; Methodology; Writing, review and editing. M.T.A.: Writing, review and editing. D.J.W.: Conceptualization; Funding acquisition. B.M.: Conceptualization; Supervision; Funding acquisition. Z.R.: Data curation; Project administration. C.M.V.: Data curation; Project administration. A.A.: Conceptualization; Funding acquisition. J.F.C.: Conceptualization; Funding acquisition. J.D.M.: Conceptualization; Funding acquisition; Supervision.

Funding

This study was supported by the Superfund Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health (grants P42ES017198 and). Additional support was provided from NIEHS grant numbers P50ES026049, R01ES032203, and P30ES017885 and the Environmental influences on Child Health Outcomes (ECHO) program grant number UH3OD023251. Support for Max Aung was provided in part by NIH award P30ES030284.

Acknowledgements

We thank the nurses and research staff who participated in cohort recruitment and follow up, as well as the Federally Qualified Health Centers (FQHC) and clinics in Puerto Rico who facilitated participant recruitment, including Morovis Community Health Center (FQHC), Prymed: Ciales Community Health Center (FQHC), Camuy Health Services, Inc. (FQHC), and the Delta OBGyn (Prenatal Clinic).

Competing Interests

The authors declare that they have no financial or other conflict of interests.

REFERENCES

1. Heudorf, U., V. Mersch-Sundermann, and J. Angerer, *Phthalates: toxicology and exposure*. Int J Hyg Environ Health, 2007. **210**(5): p. 623-34.
2. Hauser, R. and A.M. Calafat, *Phthalates and human health*. Occup Environ Med, 2005. **62**(11): p. 806-18.
3. Council, N.R., *Phthalates and cumulative risk assessment: the tasks ahead*. 2009: National Academies Press.
4. Centers for Disease Control and Prevention (CDC), *Fourth National Report on Human Exposure to Environmental Chemicals Updated Tables*. 2019.
5. Mose, T., et al., *Transplacental transfer of monomethyl phthalate and mono(2-ethylhexyl) phthalate in a human placenta perfusion system*. Int J Toxicol, 2007. **26**(3): p. 221-9.
6. Casas, M., et al., *Exposure to Bisphenol A and Phthalates during Pregnancy and Ultrasound Measures of Fetal Growth in the INMA-Sabadell Cohort*. Environ Health Perspect, 2016. **124**(4): p. 521-8.
7. Ferguson, K.K., et al., *Environmental phthalate exposure and preterm birth in the PROTECT birth cohort*. Environ Int, 2019. **132**: p. 105099.
8. Ferguson, K.K., T.F. McElrath, and J.D. Meeker, *Environmental phthalate exposure and preterm birth*. JAMA Pediatr, 2014. **168**(1): p. 61-67.
9. Swan, S.H., *Environmental phthalate exposure and the odds of preterm birth: an important contribution to environmental reproductive epidemiology*. JAMA Pediatr, 2014. **168**(1): p. 14-5.
10. Hu, J.M.Y., et al., *Associations of prenatal urinary phthalate exposure with preterm birth: the Maternal-Infant Research on Environmental Chemicals (MIREC) Study*. Can J Public Health, 2020. **111**(3): p. 333-341.
11. Wolff, M.S., et al., *Prenatal phenol and phthalate exposures and birth outcomes*. Environ Health Perspect, 2008. **116**(8): p. 1092-7.
12. Philips, E.M., V.W.V. Jaddoe, and L. Trasande, *Effects of early exposure to phthalates and bisphenols on cardiometabolic outcomes in pregnancy and childhood*. Reprod Toxicol, 2017. **68**: p. 105-118.
13. Kim, S.H. and M.J. Park, *Phthalate exposure and childhood obesity*. Ann Pediatr Endocrinol Metab, 2014. **19**(2): p. 69-75.
14. Bornehag, C.G., et al., *Association of Prenatal Phthalate Exposure With Language Development in Early Childhood*. JAMA Pediatr, 2018. **172**(12): p. 1169-1176.
15. Gascon, M., et al., *Prenatal exposure to phthalates and neuropsychological development during childhood*. Int J Hyg Environ Health, 2015. **218**(6): p. 550-8.
16. Engel, S.M., et al., *Prenatal phthalate exposure is associated with childhood behavior and executive functioning*. Environ Health Perspect, 2010. **118**(4): p. 565-71.
17. Klötting, N., et al., *Di-(2-ethylhexyl)-phthalate (DEHP) causes impaired adipocyte function and alters serum metabolites*. PLoS one, 2015. **10**(12): p. e0143190.

18. Bastos Sales, L., et al., *Analysis of lipid metabolism, immune function, and neurobehavior in adult C57BL/6JxFVB mice after developmental exposure to di (2-ethylhexyl) phthalate*. *Frontiers in endocrinology*, 2018. **9**: p. 684.
19. Cao, H., et al., *Bis-(2-ethylhexyl) Phthalate Increases Insulin Expression and Lipid Levels in Drosophila melanogaster*. *Basic & clinical pharmacology & toxicology*, 2016. **119**(3): p. 309-316.
20. Bell, F.P., *Effects of phthalate esters on lipid metabolism in various tissues, cells and organelles in mammals*. *Environmental health perspectives*, 1982. **45**: p. 41-50.
21. Hayashi, Y., et al., *Hepatic peroxisome proliferator-activated receptor α may have an important role in the toxic effects of di (2-ethylhexyl) phthalate on offspring of mice*. *Toxicology*, 2011. **289**(1): p. 1-10.
22. Shoaito, H., et al., *The Role of Peroxisome Proliferator-Activated Receptor Gamma (PPAR γ) in Mono (2-ethylhexyl) Phthalate (MEHP)-Mediated Cytotrophoblast Differentiation*. *Environmental health perspectives*, 2019. **127**(2): p. 027003.
23. Perng, W., et al., *Exposure to phthalates is associated with lipid profile in peripubertal Mexican youth*. *Environmental research*, 2017. **154**: p. 311-317.
24. Allison, K., et al., *Prenatal Maternal Phthalate Exposures and Child Lipid and Adipokine Levels at Age Six: A Study from the PROGRESS Cohort of Mexico City*. *Environmental Research*, 2020: p. 110341.
25. Jia, X., et al., *Prenatal maternal blood triglyceride and fatty acid levels in relation to exposure to di (2-ethylhexyl) phthalate: a cross-sectional study*. *Environmental health and preventive medicine*, 2015. **20**(3): p. 168-178.
26. Han, X. and R.W. Gross, *Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples*. *Mass spectrometry reviews*, 2005. **24**(3): p. 367-412.
27. Zhou, M., et al., *Metabolomic Markers of Phthalate Exposure in Plasma and Urine of Pregnant Women*. *Front Public Health*, 2018. **6**: p. 298.
28. Ferguson, K.K., et al., *Environmental phthalate exposure and preterm birth in the PROTECT birth cohort*. *Environment international*, 2019. **132**: p. 105099.
29. Meeker, J., et al., *Environmental phthalate exposure and preterm birth in the Puerto Rico Testsite for Exploring Contamination Threats (PROTECT) birth cohort*. *Environmental Epidemiology*, 2019. **3**: p. 119.
30. Aung, M., et al., *Maternal Lipidomic Signatures in Relation to Spontaneous Preterm Birth and Large-For-Gestational Age Neonates*. 2021.
31. Richardson, D.B., et al., *Analyses of case-control data for additional outcomes*. *Epidemiology*, 2007. **18**(4): p. 441-5.
32. Silva, M.J., et al., *Quantification of 22 phthalate metabolites in human urine*. *J Chromatogr B Analyt Technol Biomed Life Sci*, 2007. **860**(1): p. 106-12.
33. Silva, M.J., et al., *Environmental exposure to the plasticizer 1,2-cyclohexane dicarboxylic acid, diisononyl ester (DINCH) in U.S. adults (2000-2012)*. *Environ Res*, 2013. **126**: p. 159-63.
34. Silva, M.J., et al., *Exposure to di-2-ethylhexyl terephthalate in the U.S. general population from the 2015-2016 National Health and Nutrition Examination Survey*. *Environ Int*, 2019. **123**: p. 141-147.

35. Lessmann, F., et al., *Metabolism and urinary excretion kinetics of di(2-ethylhexyl) terephthalate (DEHTP) in three male volunteers after oral dosage*. Arch Toxicol, 2016. **90**(7): p. 1659-67.
36. Silva, M.J., et al., *Identification of di-2-ethylhexyl terephthalate (DEHTP) metabolites using human liver microsomes for biomonitoring applications*. Toxicol In Vitro, 2015. **29**(4): p. 716-21.
37. Hornung, R.W. and L.D. Reed, *Estimation of Average Concentration in the Presence of Nondetectable Values*. Applied Occupational and Environmental Hygiene, 1990. **5**(1).
38. Bligh, E.G. and W.J. Dyer, *A rapid method of total lipid extraction and purification*. Canadian journal of biochemistry and physiology, 1959. **37**(8): p. 911-917.
39. Gika, H.G., et al., *Evaluation of the repeatability of ultra-performance liquid chromatography–TOF-MS for global metabolic profiling of human urine samples*. Journal of Chromatography B, 2008. **871**(2): p. 299-305.
40. Kind, T., et al., *LipidBlast in silico tandem mass spectrometry database for lipid identification*. Nature methods, 2013. **10**(8): p. 755.
41. Schmidt, J.S., et al., *Effects of di(2-ethylhexyl) phthalate (DEHP) on female fertility and adipogenesis in C3H/N mice*. Environ Health Perspect, 2012. **120**(8): p. 1123-9.
42. Mu, X., et al., *New insights into the mechanism of phthalate-induced developmental effects*. Environ Pollut, 2018. **241**: p. 674-683.
43. Schoonjans, K., B. Staels, and J. Auwerx, *The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation*. Biochim Biophys Acta, 1996. **1302**(2): p. 93-109.
44. Latruffe, N. and J. Vamecq, *Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism*. Biochimie, 1997. **79**(2-3): p. 81-94.
45. Haemmerle, G., et al., *ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1*. Nat Med, 2011. **17**(9): p. 1076-85.
46. Zechner, R., et al., *FAT SIGNALS--lipases and lipolysis in lipid metabolism and signaling*. Cell Metab, 2012. **15**(3): p. 279-91.
47. Bobinski, R. and M. Mikulska, *The ins and outs of maternal-fetal fatty acid metabolism*. Acta Biochim Pol, 2015. **62**(3): p. 499-507.
48. Ogundipe, E., et al., *Peri-conception maternal lipid profiles predict pregnancy outcomes*. Prostaglandins Leukot Essent Fatty Acids, 2016. **114**: p. 35-43.
49. Khaire, A., et al., *Maternal fats and pregnancy complications: Implications for long-term health*. Prostaglandins Leukot Essent Fatty Acids, 2020. **157**: p. 102098.
50. Wang, Y., et al., *Dietary variables and glucose tolerance in pregnancy*. Diabetes Care, 2000. **23**(4): p. 460-4.
51. Meeker, J.D., et al., *Urinary phthalate metabolites in relation to preterm birth in Mexico city*. Environ Health Perspect, 2009. **117**(10): p. 1587-92.

Figure Legends:

Figure 1. Manhattan plot showing individual lipids associated with urinary phthalate metabolite concentrations. Models were adjusted for maternal age, maternal education, fetal sex, pre-pregnancy BMI, and weight gain during pregnancy.




Figure 2. Percent change in lipid subgroup sum z-score associated with urinary phthalate metabolite concentrations. Effect estimates are presented as percent change (%) for IQR increase in exposure biomarker concentration^{ab}. Models were adjusted for maternal age, maternal education, fetal sex, pre-pregnancy BMI, and weight gain during pregnancy.




Figure 3. Correlation matrix between specific gravity corrected concentrations of phthalate metabolites and all lipid classes




Figure 4. Percent change in lipid class sum z-score associated with urinary phthalate metabolite concentrations. Effect estimates are presented as percent change (%) for IQR increase in exposure biomarker concentration^{ab}. Models were adjusted for maternal age, maternal education, fetal sex, pre-pregnancy BMI, and weight gain during pregnancy.

